BNP/PUT/ELI LILLY & CO/750/0.1/21.03.25 | Market Closed - Boerse Frankfurt Warrants 01:20:30 04/07/2024 am IST | ||
| 3.02 EUR | +5.96% |
|
| Current month | +12.18% | ||
| 1 month | -31.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 3.04 | +6.67% |
| 02/24/02 | 2.85 | +7.95% |
| 01/24/01 | 2.64 | -2.58% |
| 28/24/28 | 2.71 | -1.09% |
| 27/24/27 | 2.74 | -5.84% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC9XJB |
| ISIN | DE000PC9XJB0 |
| Date issued | 15/05/2024 |
| Strike | 750 $ |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 5.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.54 € |
|---|---|
| Lowest since issue | 2.56 € |
| Spread | 0.11 € |
| Spread % | 3.51% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
